Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

  1. de Andrés-Nogales, F.
  2. Oyagüez, I.
  3. Álvarez-Sala, L.A.
  4. García-Bragado, F.
  5. Navarro, A.
  6. González, P.
  7. Elías, I.
  8. Soto, J.
Zeitschrift:
Pharmacoeconomics - Spanish Research Articles

ISSN: 1989-5453,  1695-405X

Datum der Publikation: 2017

Ausgabe: 14

Nummer: 1

Seiten: 7-18

Art: Artikel

DOI: 10.1007/S40277-016-0064-8 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus